⌕
Merck · MRK · NYSE
Tenet 41 · Weak
Compare
$144.46−2.23%At closeTenet 41 · Weak
$144.46−3.30 (−2.23%)
At close: Nov 16, 2026, 4:00 PM ET· NYSE · USD
$144.94+0.48 (+0.33%)
After hours: Nov 16, 2026, 5:50 PM ET

Merck (MRK) News

What's actually happening: chronological and provenance-stamped. News is context, not a signal.

Sources News publishers NewsHow we compute thisNot investment advice

● The Motley FoolNov 16, 2026 · 14:20 ETEARNINGS EXPECTED BY FEB 3
Is Merck's Stock Still a Good Buy at $150?

Merck is coming off a strong quarter as revenue from a new version of Keytruda boosted its top line. It remains likely, however, that its revenue will drop off in the near future as key patents on Keytruda are expiring i…

● Defense WorldNov 15, 2026 · 09:49 ETEARNINGS EXPECTED BY FEB 3
Merck & Co., Inc. $MRK Stock: Aberdeen Group plc Decreases Stake

Aberdeen Group plc cut its holdings in Merck and Co., Inc. (NYSE: MRK) by 87.4% during a recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 544,186 sh…

● Business WireNov 13, 2026 · 06:40 ETCOMPANY'S OWN WORDS
Merck Receives Positive EU CHMP Opinion to Expand Marketing Authorization for ENFLONSIA® (clesrovimab) to Include Children Up to 24 Months of Age Who Remain Vulnerable to Severe RSV Disease Through Their Second RSV Season

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicin…

● Business WireNov 13, 2026 · 06:35 ETCOMPANY'S OWN WORDS
Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) in Combination With Lenvatinib for Adults With Advanced Renal Cell Carcinoma With a Clear Cell Component (ccRCC) Following Treatment With an Anti-PD-1/PD-L1 Therapy

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) …

● MarketBeatNov 12, 2026 · 11:16 ETEARNINGS EXPECTED BY FEB 3
What Merck KGaA (MRK) Said on Its Q3 Earnings Call

Merck KGaA ETR: MRK raised its full-year 2026 outlook for the third time after faster third-quarter sales growth in its Life Science and Electronics businesses offset pressure on its Healthcare portfolio.…

● Business WireNov 12, 2026 · 06:45 ETCOMPANY'S OWN WORDS
Merck to Participate in the Jefferies Global Healthcare Conference in London

RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Participate in the Jefferies Global Healthcare Conference in London.…

● BenzingaNov 11, 2026 · 09:56 ET
EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat

The next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead Sciences, Inc. (NASDAQ:GILD) facing more immediate exposure a…

● Business WireNov 10, 2026 · 13:14 ET
FDA Approves PIMJETMI® (pimicotinib) for Patients with Tenosynovial Giant Cell Tumor

DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, announced today that the U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a once-daily oral colony stimul…

● Business WireNov 9, 2026 · 13:05 ETCOMPANY'S OWN WORDSEARNINGS EXPECTED BY FEB 3
Merck Announces Positive Results from Phase 2b Trial of Efinopegdutide in Adults with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Stage 2-3 Fibrosis

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of positive results from the company's Phase 2b clinical trial that evaluated the s…

● Zacks Investment ResearchNov 9, 2026 · 12:41 ET
INVA or MRK: Which Is the Better Value Stock Right Now?

Investors with an interest in Large Cap Pharmaceuticals stocks have likely encountered both Innoviva (INVA) and Merck (MRK). But which of these two stocks presents investors with the better value opportunity right now?…

● Zacks Investment ResearchNov 9, 2026 · 09:51 ET
MRK's 2027 Outlook Challenging, Long-Term Prospects Promising

Merck's 2027 growth faces generic pressures, vaccine weakness and Keytruda slowdown, but its expanding pipeline offers promising long-term potential.…

● Defense WorldNov 8, 2026 · 04:02 ETEARNINGS EXPECTED BY FEB 3
Merck & Co., Inc. $MRK Stock Purchased by Asset One Wealth Management LLC

Asset One Wealth Management LLC boosted its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 55.2% in a recent quarter, according to its most recent Form 13F filing with the SEC. The firm owned 10,416 shares of t…

● Zacks Investment ResearchNov 6, 2026 · 14:11 ET
Merck Stock Shows Sustained Strength: Time to Buy, Sell or Hold?

MRK's growth momentum faces patent and competitive risks as Keytruda demand and new launches support growth.…

● Defense WorldNov 6, 2026 · 04:19 ETEARNINGS EXPECTED BY FEB 3
Merck & Co., Inc. $MRK Stock Acquired by Compass Financial Management LLC

Compass Financial Management LLC lifted its position in shares of Merck and Co., Inc. (NYSE: MRK) by 256.3% during a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission. Th…

● Zacks Investment ResearchNov 5, 2026 · 09:50 ETEARNINGS EXPECTED BY FEB 3
MRK's Keytruda & Gardasil Sales Rise in Q3: Can the Momentum Last?

Merck's Keytruda and Gardasil sales rise in Q3, but inventory reversals, slowing demand and looming competition could challenge growth.…

● Defense WorldNov 5, 2026 · 05:01 ETEARNINGS EXPECTED BY FEB 3
Merck & Co., Inc. $MRK Shares Sold by Boston Trust Walden Corp

Boston Trust Walden Corp cut its holdings in shares of Merck and Co., Inc. (NYSE: MRK) by 12.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 39…

● Business WireNov 3, 2026 · 06:45 ETCOMPANY'S OWN WORDS
Merck Initiates Phase 3 Study Evaluating Ohtuvayre® (ensifentrine) for the Prevention of COPD Exacerbations in Adult Patients Receiving Standard of Care With a History of Exacerbations

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MERCK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the initiation of ENHANCE-3 (NCT07874815), a Phase 3 randomized clinical trial evalu…

● Business WireNov 2, 2026 · 06:45 ETCOMPANY'S OWN WORDS
Merck to Present New Data from Its Broad Oral HIV Portfolio and Pipeline at HIV Glasgow 2026

RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--New data include Phase 3 subgroup analyses and patient-reported outcomes of investigational once-weekly oral combination of ISL/LEN.…

● Business WireOct 30, 2026 · 11:00 ET
Lost Money on Merck & Co., Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 1.76% Share Price Drop

LOS ANGELES--(BUSINESS WIRE)--Investors who lost money on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securit…

● Business WireOct 30, 2026 · 09:00 ET
Did You Lose Money on Merck & Co., Inc. Stock? The Law Offices of Howard G.

BENSALEM, Pa.--(BUSINESS WIRE)--Investors who suffered losses on Merck & Co., Inc. ("Merck" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is co…

● Business WireOct 29, 2026 · 17:31 ET
Lost Money on Merck & Co., Inc. Shares? The Law Offices of Frank R.

LOS ANGELES--(BUSINESS WIRE)--Merck & Co., Inc. ("Merck" or the "Company") investors who lost money may have claims to recover their losses. The Law Offices of Frank R. Cruz today announced it is investigating potential …

Expected by Feb 3. Report dates come from the data provider's upcoming-earnings feed and are its estimate, not a date the company has set.

Article counts from the last market-wide feed page, across every symbol we track and not just MRK · day move from the quote feed. Equal counts are listed alphabetically, not ranked. Coverage ≠ importance.

The feed is purely chronological. No materiality ranking, no hidden sentiment score. Timestamps are publisher-reported and arrive with no timezone, so they are read and shown on the US market clock (ET); thumbnails come from each article's image field; day moves from the quote feed. Copies of the same story are collapsed on link or normalized headline, and a company's press release is kept over any syndicated copy of it; "company's own words" means the release title leads with the company's name and the wire names no other organisation first as its issuer; "earnings-tied" is a keyword match while a report date is upcoming. Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.